Macronutrient intake and cancer: How does dietary restriction influence tumor growth and why should we care?

Cancer Prevention Research

Volumn 2, Issue 8, 2009, Pages 698-701

  Pollak, Michael ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR ALPHA;

BREAST CANCER; BREAST CARCINOGENESIS; CALORIC RESTRICTION; CANCER MODEL; CELL PROLIFERATION; DIET RESTRICTION; DIETARY INTAKE; HUMAN; MACRONUTRIENT; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; NUTRIENT SUPPLY; OVERNUTRITION; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH;

ANIMALS; ATTENTION; ATTITUDE TO HEALTH; CALORIC RESTRICTION; CELL GROWTH PROCESSES; CELL TRANSFORMATION, NEOPLASTIC; EATING; ENDOCRINE SYSTEM; FOOD; HUMANS; HYPERPHAGIA; MICE; NEOPLASMS;

EID: 77950851891     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0134     Document Type: Review

References (31)

1. Rous P. The influence of diet on transplanted and spontaneous tumors. J Exp Med 1914;20:351-413.
2. Pollak M. Do cancer cells care if their host is hungry? Cell Metab 2009;9:401-403
3. Rogozina OP, Bonorden MJL, Grande JP, Cleary MP. Serum insulin-like growth factor-1 and mammary tumor development in ad libitum-fed, chronic calorie-restricted and intermittent calorie-restricted MMTV-TGF-α mice. Cancer Prev Res 2009;2:712-719
4. Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res 2008;1:369-375
5. Law JH, Habibi G, Hu K, et al. Phosphorylated insulin-like growth factor-1/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008;68:10238-10246
6. Cox ME, Gleave ME, Zakikhani M, et al. Insulin receptor expression by human prostate cancers. Prostate 2009;69:33-40.
7. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 2007;13:671-686 (Pubitemid 46510744)
8. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-928
9. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279:563-566 (Pubitemid 28067285)
10. Ma J, Li H, Giovannucci E, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 2008;9:1039-1047
11. Dunn SE, Kari FW, French J, et al. Dietary restriction reduces IGF-I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53 deficient mice. Cancer Res 1997;57:4667-4672 (Pubitemid 27468963)
12. Moore T, Beltran L, Carbajal S, et al. Dietary energy balance modulates signaling through the Akt/ mammalian target of rapamycin pathways in multiple epithelial tissues. Cancer Prev Res 2008;1: 65-76.
13. Venkateswaran V, Haddad AQ, Fleshner NE, et al. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst 2007;99:1793-1800 (Pubitemid 351767208)
14. Majeed N, Blouin MJ, Kaplan-Lefko PJ, et al. A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. Oncogene 2005;24:4736-4740 (Pubitemid 41032610)
15. Pollak M, Blouin MJ, Zhang JC, et al. Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone anatgonist. Br J Cancer 2001;85:428-430 (Pubitemid 32747713)
16. Pearson KJ, Lewis KN, Price NL, et al. R.de Cabo, Nrf2 mediates cancer protection but not prolongevity induced by caloric restriction. Proc Natl Acad Sci U S A 2008;105:2325-2330
17. Kalaany NY, Sabatini DM. Tumours with PI3K activation are resistant to dietary restriction. Nature 2009;458:725-731
18. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-1638 (Pubitemid 36459468)
19. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-591 (Pubitemid 39025053)
20. Palma D, Pickles T. Prostate cancer and host metabolic factors. Lancet Oncol 2008;9:1022-1023
21. Ingram DK, Zhu M, Mamczarz J, et al. Calorie restriction mimetics: an emerging research field. Aging Cell 2006;5:97-108. (Pubitemid 44056501)
22. Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene. In press 2009.
23. White MF. Metformin and insulin meet in a most atypical way. Cell Metab 2009;9:485-487
24. He L, Sabet A, Djedjos S, et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 2009;137:635-646
25. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310:1642-1646 (Pubitemid 41780780)
26. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269-10273 (Pubitemid 44799743)
27. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007;67: 10804-10812 (Pubitemid 350145909)
28. Algire C, Zakikhani M, Blouin M-J, Shuai JH, Pollak M. Metformin attenuates the stimulatory effect of a high energy diet on in vivo H59 carcinoma growth. Endocr Relat Cancer 2008;15:833-839
29. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-1305 (Pubitemid 40813563)
30. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29:254-258 (Pubitemid 44106500)
31. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. Epub 2009 Jun 1.